Doubling Down On Innovation, Recovery

September 17, 2021

Not that long ago, the overall mood in the pharmaceutical and biotechnology industries was somewhat gloomy. The public image of the industry had fallen from being one of the most respected to being characterized as the greedy villain behind high drug prices. Innovation by the large pharma companies had slowed dramatically, even with a slew of innovations focused on speeding up the drug discovery process and on new technologies.

Read the source article at PharmExec
2021-09-14 20:55:00

Share This Story!